Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.

被引：2
|
作者：
O'Brien, Mary E. R.
Eberhardt, Wilfried Ernst Erich
Altorki, Nasser K.
Spigel, David R.
Crino, Lucio
Tsai, Chun-Ming
Cho, Eun Kyung
Kim, Joo-Hang
Szczesna, Aleksandra
Hoffman, Philip C.
Burghuber, Otto
Keshavjee, Shaf
Orlov, Sergey
Serwatowski, Piotr
Wang, Jiuzhou
Foley, Margaret A.
Horan, Julie D.
Park, Jung Wook
Shepherd, Frances A.
Kelly, Karen
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol,Ruhrlandklin, Essen, Germany
[3] New Presbyterian Hosp Weill Cornell Med Coll, New York, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Perugia, I-06100 Perugia, Italy
[6] Taipei Vet Gen Hosp, Dept Chest Med, Div Thorac Oncol, Taipei, Taiwan
[7] Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan
[8] Gachon Univ, Gil Med Ctr, Inchon, South Korea
[9] Yonsei Univ Heath Syst, Yonsei Canc Ctr, Seoul, South Korea
[10] Mazowieckie Ctr Leczenia Chorob Pluc, Otwock, Poland
[11] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[12] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[13] Univ Hlth Network, Princess Margaret Canc Ctr, Div Thorac Surg, Toronto, ON, Canada
[14] St Petersburg Med Univ, St Petersburg, Russia
[15] Specjalisty Szpital, Szczecin, Poland
[16] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[17] Novella Clin, Boulder, CO USA
[18] Astellas Pharma Global Dev, Northbrook, IL USA
[19] Princess Margaret Canc Ctr, Toronto, ON, Canada
[20] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7535
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).
    Paz-Ares, Luis G.
    Garon, Edward B.
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Cho, Byoung Chul
    Castro, Gilberto
    De Marchi, Pedro
    Felip, Enriqueta
    Goto, Yasushi
    Greystoke, Alastair
    Lu, Shun
    Lim, Darren Wan Teck
    Papadimitrakopoulou, Vassiliki
    Reck, Martin
    Solomon, Benjamin J.
    Spigel, David R.
    Tan, Daniel Shao-Weng
    Thomas, Michael
    Yang, James Chih-Hsin
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
    Bagley, Stephen
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1289 - S1289
  • [43] A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC).
    Rigas, JR
    Dragnev, KH
    Petty, WJ
    Nugent, WC
    Memoli, VA
    Black, CC
    Lewis, LD
    Loewen, G
    Negro-Vilar, A
    Dmitrovsky, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 654S - 654S
  • [44] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [45] Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer
    Carser, Judith Elizabeth
    Summers, Yvonne Jane
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) : 1040 - 1041
  • [46] Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).
    O'Brien, Mary E. R.
    Kelly, Karen
    Altorki, Nasser K.
    Eberhardt, Wilfried Ernst Erich
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Hoffman, Philip C.
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Joe
    Foley, Margaret A.
    Horan, Julie D.
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] RANDOMIZED PHASE II STUDY OF SUNITINIB (SU) PLUS ERLOTINIB (E) VS. PLACEBO (P) PLUS E FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
    Groen, H. J. M.
    Socinski, M.
    Grossi, F.
    Juhasz, E.
    Gridelli, C.
    Baas, P.
    Usari, T.
    Tye, L.
    Chao, R.
    Blumenschein, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 139 - 139
  • [48] Sunitinib in Combination with Erlotinib for the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Thongprasert, Sumitra
    Govindan, Ramaswamy
    Krzakowski, Maciej
    Szczesna, Aleksandra
    Strausz, Janos
    Makhson, Anatoly
    Tye, Lesley
    Zhang, Ke
    Chao, Richard C.
    Scagliotti, Giorgio V.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S375 - S375
  • [49] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [50] A PHASE 2 TRIAL OF LINIFANIB TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Tan, E.
    Goss, G. D.
    Salgia, R.
    Besse, B.
    Gandara, D. R.
    Hanna, N.
    Ricker, J. L.
    Qian, J.
    Carlson, D. M.
    Soo, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 139 - 139
12345